Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Hyperuricemia as a risk factor for cardiovascular disease..
Expert Rev Cardiovasc Ther. 13(1), 19-20.
(2015). Nonalcoholic fatty liver disease and statins..
Metabolism. 64(10), 1215-23.
(2015). Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome..
World J Gastroenterol. 21(25), 7860-8.
(2015). Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention..
Curr Med Res Opin. 31(2), 191-5.
(2015). Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly..
Atherosclerosis. 238(2), 182-4.
(2015). Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.
Expert Opin Pharmacother. 16(10), 1449-61.
(2015). Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?.
Curr Vasc Pharmacol. 13(3), 368-80.
(2015). Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy..
Expert Rev Cardiovasc Ther. 13(9), 1059-66.
(2015). The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!.
Curr Med Res Opin. 30(9), 1701-5.
(2014). Achieving lipid targets in primary care settings..
Curr Med Res Opin. 30(10), 1971-4.
(2014). Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI..
Nat Rev Nephrol. 10(1), 8-9.
(2014).
(2014). Are statins 'IDEAL' for non-alcoholic fatty liver disease?.
Curr Med Res Opin. 30(2), 229-31.
(2014). Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention..
Curr Med Res Opin. 30(1), 55.
(2014). Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review..
Angiology. 65(4), 284-93.
(2014). Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview..
Curr Vasc Pharmacol. 12(4), 627-41.
(2014). Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study..
Open Cardiovasc Med J. 8, 55-60.
(2014). Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics..
Nat Rev Cardiol. 11(2), 72-4.
(2014). Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?)..
Curr Vasc Pharmacol. 12(6), 867-9.
(2014). Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?)..
Curr Vasc Pharmacol. 12(6), 870-2.
(2014). Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report..
Curr Vasc Pharmacol. 12(3), 505-11.
(2014). Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy..
Curr Vasc Pharmacol.
(2014). The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes..
Lancet Diabetes Endocrinol. 2(5), 362-3.
(2014). Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure..
Curr Pharm Des. 20(40), 6306-13.
(2014). Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness..
J Am Soc Hypertens. 8(2), 74-82.
(2014).